BioNTech (NASDAQ:BNTX) Receives “Buy” Rating from Berenberg Bank

BioNTech (NASDAQ:BNTX)‘s stock had its “buy” rating reiterated by analysts at Berenberg Bank in a research note issued to investors on Friday,MarketScreener reports.

A number of other research analysts also recently issued reports on the company. UBS Group raised BioNTech to a “hold” rating in a report on Thursday, December 4th. Morgan Stanley restated an “overweight” rating and set a $134.00 price target on shares of BioNTech in a research report on Monday, November 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioNTech in a report on Friday, January 9th. JPMorgan Chase & Co. reduced their target price on BioNTech from $121.00 to $120.00 and set a “neutral” rating for the company in a research note on Thursday, October 23rd. Finally, The Goldman Sachs Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and increased their price objective for the company from $115.00 to $142.00 in a report on Friday, January 16th. Eleven analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $140.03.

BioNTech Stock Up 0.4%

NASDAQ:BNTX opened at $118.47 on Friday. The company has a current ratio of 7.12, a quick ratio of 7.02 and a debt-to-equity ratio of 0.01. The company’s 50 day moving average is $99.14 and its two-hundred day moving average is $103.69. BioNTech has a twelve month low of $81.20 and a twelve month high of $126.77. The company has a market cap of $26.68 billion, a PE ratio of -45.05 and a beta of 1.40.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of $0.75 by ($0.89). The company had revenue of $1.78 billion for the quarter, compared to analyst estimates of $1.21 billion. BioNTech had a negative return on equity of 3.03% and a negative net margin of 17.91%.BioNTech’s revenue for the quarter was up 22.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.81 earnings per share. Analysts anticipate that BioNTech will post -3.88 EPS for the current year.

Institutional Trading of BioNTech

Hedge funds have recently added to or reduced their stakes in the company. Financial Consulate Inc. purchased a new stake in shares of BioNTech during the 3rd quarter worth $36,000. Huntington National Bank grew its holdings in shares of BioNTech by 1,266.7% during the third quarter. Huntington National Bank now owns 410 shares of the company’s stock worth $40,000 after purchasing an additional 380 shares during the last quarter. LRI Investments LLC boosted its position in shares of BioNTech by 234.6% in the 2nd quarter. LRI Investments LLC now owns 445 shares of the company’s stock valued at $47,000 after purchasing an additional 312 shares during the period. Tower Research Capital LLC TRC grew its stake in BioNTech by 118.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after buying an additional 305 shares during the last quarter. Finally, Hantz Financial Services Inc. lifted its stake in BioNTech by 472.0% in the second quarter. Hantz Financial Services Inc. now owns 572 shares of the company’s stock valued at $61,000 after buying an additional 472 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.